OncoSec Medical Inc (ONCSQ)

[lasers]

Dr Pierce, formerly Merck, and now OncoSec CMO has changed that.

DD Longs that understand the impact of a Dr. Pierce would be adding more shares in a "Buy, Hold, Accumulate" investment strategy.

In addition this 2013 achieved milestone is directly related to Dr. Pierce's Clinical Trials with Merck.

OncoSec Medical enters sponsored research agreement with Old Dominion University for combination study in melanoma. Study to evaluate the effects of ImmunoPulse in combination with Anti-CTLA4, Anti-PD1 and Anti-PDL-1 therapies.

I look forward to the "Biotech Showcase" on Jan 14 to hear more details about ImmunoPulse in combination with Anti-CTLA4, Anti-PD1 and Anti-PDL-1 therapies and what studies/trials OncoSec has planned. This is a major pursuit by OncoSec for humans skin cancers therapies and Dr. Pierce is leading the way for OncoSec.